CBLLCeriBell, Inc.
Is the business good?
Margins steady. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Margins have held roughly steady, a stable cost structure.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is CBLL?
CeriBell, Inc. keeps −69% of every revenue dollar as operating profit, against 2.1% for the median Medical Devices name.
Operating margin · Medical Devices median 2.1% · 12 months to Q2 2026
- Share count, year on year
- +4.8%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 23%
R&D as % of revenue
- Gross margin
- 89%
Gross margin
| Year | Operating margin |
|---|---|
| FY2023 | −66% |
| FY2024 | −61% |
| FY2025 | −66% |
Details›
- Gross margin12 months to Q2 2026
- 89%
- Operating margin12 months to Q2 2026
- −69%
- Net margin12 months to Q2 2026
- −65%
- Free cash flow margin
- −54%
- R&D as % of revenue
- 23%
- Revenue, trailing twelve months
- $102M
- Free cash flow, trailing twelve months
- −$55M
- Net income, trailing twelve months
- −$66M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Medical Devices
The closest names by size in the same industry